PTC Therapeutics
PTCT
183 hedge funds and large institutions have $2.78B invested in PTC Therapeutics in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 54 reducing their positions, and 19 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 54
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6% more call options, than puts
Call options by funds: $4.88M | Put options by funds: $4.6M
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0.36% more ownership
Funds ownership: 105.28% → 105.64% (+0.36%)
0% more funds holding
Funds holding: 183 → 183 (0)
11% less capital invested
Capital invested by funds: $3.14B → $2.78B (-$360M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$30.8M |
| 2 |
AC
Armistice Capital
New York
|
+$20.7M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.7M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$13M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$40.1M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.94M |
| 4 |
Morgan Stanley
New York
|
-$5.65M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.61M |
PTCT Hedge Fund Activity: Q3 2021 in Review
183 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2021, worth a combined $2.78B — down 11% from $3.14B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PTCT positions and 19 closed out — a net gain of 1 holder — while 68 added to existing stakes and 54 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $30.8M. The largest seller was Franklin Resources, cutting an estimated $40.1M.
- 183 institutional investors held PTC Therapeutics (PTCT) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $2.78B of PTC Therapeutics stock for Q3 2021, down 11% quarter-over-quarter.
- 20 funds opened new PTC Therapeutics positions in Q3 2021 and 19 closed out, a net change of +1 holder.
- The largest PTC Therapeutics buyer in Q3 2021 was Camber Capital Management, an estimated $30.8M added.
- The largest PTC Therapeutics seller in Q3 2021 was Franklin Resources, an estimated $40.1M sold.
Based on aggregated 13F filings for Q3 2021.